To evaluate the efficacy of baxdrostat in treating resistant hypertension in adults with uncontrolled blood pressure despite existing antihypertensive therapies.
Key Findings:
Baxdrostat 2 mg resulted in a 15.7 mmHg reduction in seated systolic blood pressure from baseline, corresponding to a 9.8 mmHg placebo-adjusted reduction.
Baxdrostat 1 mg led to a 14.5 mmHg reduction from baseline, with an 8.7 mmHg placebo-adjusted reduction.
The placebo group showed a 5.8 mmHg reduction in seated systolic blood pressure.
Baxdrostat selectively inhibits aldosterone synthase without affecting cortisol levels.
Interpretation:
The significant reductions in blood pressure with baxdrostat suggest it may be an effective treatment option for patients with resistant hypertension, potentially reducing the risk of serious cardiovascular events.
Limitations:
The study duration was limited to 12 weeks, which may not fully capture long-term efficacy and safety.
The trial population may not represent all demographics affected by resistant hypertension, particularly in terms of age, ethnicity, and comorbid conditions.
Conclusion:
Baxdrostat is the first aldosterone synthase inhibitor approved for resistant hypertension, offering a new therapeutic option for patients with uncontrolled blood pressure.
